Showing results (91-100 of 124) with videos related to
Sort By:
Pageof 13
Clinical Chemistry|December 3, 2014
Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudyZiad Hijazi, Agneta Siegbahn, Ulrika Andersson, et al.Circulation|June 25, 2015
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialAlvaro Avezum, Renato D Lopes, Phillip J Schulte, et al.European Heart Journal. Cardiovascular Pharmacotherapy|August 18, 2016
Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trialJustin A Ezekowitz, Basil S Lewis, Renato D Lopes, et al.Neurology|February 22, 2019
Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophyVittoria Lombardi, Giorgia Querin, Oliver J Ziff, et al.Nature Reviews. Neurology|July 3, 2013
New treatments for mitochondrial disease-no time to drop our standardsGerald Pfeffer, Rita Horvath, Thomas Klopstock, et al.American Heart Journal|March 10, 2010
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationaleRenato D Lopes, John H Alexander, Sana M Al-Khatib, et al.Journal of the American College of Cardiology|October 11, 2014
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trialGreg Flaker, Renato D Lopes, Elaine Hylek, et al.American Heart Journal|May 16, 2016
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trialRaffaele De Caterina, Ulrika Andersson, John H Alexander, et al.European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.Annals of Clinical and Translational Neurology|December 15, 2021
Genetic defects are common in myopathies with tubular aggregatesQiang Gang, Conceição Bettencourt, Stefen Brady, et al.Pageof 13